Actively Recruiting
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-23
200
Participants Needed
6
Research Sites
278 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings, comprehensive cognitive assessments, neuroimaging and DNA (copy number variant) analyses (in families and patients who agree), and follow-up of course of illness, cognitive status and treatment response to specific antipsychotic drugs. The goal of the study is to test a prior hypothesis about clinical subgroups in this population and to test whether these subgroups predict antipsychotic medication response.
CONDITIONS
Official Title
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children and young adults ages 7 to 20 years with psychotic disorder onset between 7 and 17 years
- Hospitalized or receiving outpatient treatment for an acute or chronic psychotic episode
- Diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder not otherwise specified, or major depressive episode with psychotic features according to DSM-V
- Written informed consent signed by parents or legal guardians and by the minor patient if capable
- Written informed consent signed by the patient if they are an adult and clinically stable (not delusional)
- Has health insurance coverage from Social Security (France), excluding AME coverage
- For parents or siblings participating in genetic part: parents have no specific criteria
- Siblings eligible if there are at least two first-degree relatives with psychotic disorders in the family
- Written informed consent for genetic study signed by participating parents and siblings
- Has health insurance coverage from Social Security (France), excluding AME coverage
You will not qualify if you...
- Moderate or severe intellectual deficiency with IQ less than 50
- Psychosis caused by medical illness, medication effects, or substance abuse
- Diagnosis of bipolar disorder
- Patients under legal guardianship
- Contraindications to MRI for those participating in neuroimaging part
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Fondation Vallée, Gentilly
Gentilly, France, 94257
Not Yet Recruiting
2
CHRU de Lille
Lille, France, 59037
Not Yet Recruiting
3
CHU de Nice
Nice, France, 62000
Not Yet Recruiting
4
Pitié Salpétrière
Paris, France, 75013
Actively Recruiting
5
CHU de Rouen
Rouen, France, 76031
Not Yet Recruiting
6
CHU de Rouvray
Rouen, France, 76031
Not Yet Recruiting
Research Team
C
Claudine LAURENT-LEVINSON, M.D., Ph.D.
CONTACT
A
Anne BISSERY
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here